Copyright
©The Author(s) 2024.
World J Crit Care Med. Mar 9, 2024; 13(1): 89026
Published online Mar 9, 2024. doi: 10.5492/wjccm.v13.i1.89026
Published online Mar 9, 2024. doi: 10.5492/wjccm.v13.i1.89026
Number | Summary of consensus statements |
1 | There is the need for adjuvant therapy (CytoSorb® haemoadsorption) in the management of refractory septic shock patients, when the standard of care is insufficient |
2 | In refractory septic shock cycle, CytoSorb® ideally be initiated within a maximum of 24 h after diagnosis and start of standard therapy |
3 | In the initiation of CytoSorb® therapy in refractory septic shock patient, IL-6 levels are not a pre-requisite or mandatory parameter for decision making |
4 | In a subset of patients, more than one CytoSorb® adsorber may be required to achieve sufficient haemodynamic stabilization |
5 | In continuation of CytoSorb® therapy, the absorber should be changed after 6-24 h depending on the clinical course and the machine type availability |
6 | CytoSorb® therapy is generally a safe therapy |
7 | Sepsis-induced AKI requiring RRT is not a prerequisite to initiate CytoSorb® therapy in refractory septic shock patients |
8 | The evaluation of the efficacy of CytoSorb® therapy should be based on endpoints like haemodynamic stabilization, inflammatory biomarkers, and/or improvement in the organ function, instead of mortality |
9 | The (displayed, Figure 2) flowchart can be helpful to a doctor very new to the therapy to ensure a certain level of best practice |
- Citation: Mehta Y, Ansari AS, Mandal AK, Chatterjee D, Sharma GS, Sathe P, Umraniya PV, Paul R, Gupta S, Singh V, Singh YP. Systematic review with expert consensus on use of extracorporeal hemoadsorption in septic shock: An Indian perspective. World J Crit Care Med 2024; 13(1): 89026
- URL: https://www.wjgnet.com/2220-3141/full/v13/i1/89026.htm
- DOI: https://dx.doi.org/10.5492/wjccm.v13.i1.89026